구조모아 (StructureMoa)항암 chemical structure spider web
방문타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-6 · 마지막 9월 2일
현재 선택: 5개 · Data Tier에서 열림
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | durvalumab (Imfinzi, MEDI4736) AstraZeneca·PD-L1 750 trials·t½ ~21 days (10 mg/kg q2w historical; flat mg dosing per current label) | ||||
|---|---|---|---|---|---|
Overview Program | Keytruda (pembrolizumab) | Opdivo (nivolumab) | Herceptin (trastuzumab) | Imfinzi (durvalumab) | Tecentriq (atezolizumab) |
Overview Company | Merck | Bristol Myers Squibb | Roche / Genentech | AstraZeneca | Roche / Genentech |
Overview Modality | ANTIBODY | ANTIBODY | ANTIBODY | ANTIBODY | ANTIBODY |
Overview Target | PD-1 | PD-1 | HER2 | PD-L1 | PD-L1 |
Overview Indication | Multiple solid tumors | Melanoma, NSCLC, RCC, HCC, MSI-H tumors, and others | HER2+ breast cancer, HER2+ gastric/GEJ adenocarcinoma | NSCLC (Stage III consolidation), SCLC, biliary tract, HCC | NSCLC, SCLC, HCC, TNBC, urothelial carcinoma, and others |
Overview Phase | APPROVED | APPROVED | APPROVED | APPROVED | APPROVED |
Overview Status | APPROVED | APPROVED | APPROVED | APPROVED | APPROVED |
Overview Content status | Curated Core | Curated Core | Curated Core | Curated Core | Curated Core |
Overview Data Confidence | Data Confidence · High | Data Confidence · High | Data Confidence · High | Data Confidence · High | Data Confidence · High |
Overview Development Signal | Development Signal · Established | Development Signal · Established | Development Signal · Established | Development Signal · Established | Development Signal · Established |
Overview Approval status | FDA approved | FDA approved | FDA approved | FDA approved | FDA approved |
Positioning Key differentiator | Broad tumor-agnostic biomarker strategies (MSI-H, TMB) | novel approach to enhance antitumor therapy using aPD1 and aCTLA-4 | novel bifunctional chelator (2E-C-NETA) for applications in 177 Lu-based TRT | novel small molecule A 2A R antagonist which inhibits downstream signaling and increases T cell function as well as a novel m | novel agents have been approved in recent years (including systemic pembrolizumab, nogapendekin alfa inbakicept-pmln, N-803), |
Positioning Known limitation | Loss of antigen presentation (β2M, JAK1/2), alternate checkpoints (TIM-3, LAG-3), and immunosuppressive TME. | Loss of MHC-I/antigen presentation, β2M/JAK mutations, TIM-3/LAG-3 upregulation. | resistance to trastuzumab-based targeted therapy and limited intratumoral antibody penetration continue to restrict clinical outcomes | escape detection by the immune system | resistance to existing therapies |
Positioning Development positioning | Global IO standard | — | — | — | — |
MoA Mechanism | Pembrolizumab is an IgG4 humanized monoclonal antibody that binds PD-1 on T cells and blocks interaction with PD-L1 and PD-L2, releasing PD-1 pathway-mediated inhibition of the immune response, including antitumor response. | Nivolumab is a human IgG4 monoclonal antibody that binds the PD-1 receptor on T cells, blocking interaction with PD-L1 and PD-L2 and releasing PD-1 pathway-mediated inhibition of antitumor immune responses. | Trastuzumab binds domain IV of HER2, inhibiting ligand-independent HER2 signaling, mediating ADCC via Fcγ receptors, and inducing internalization/degradation of HER2. | Durvalumab inhibits PD-L1 binding to PD-1 and CD80 (B7.1), counteracting tumor immune evasion and enhancing cytotoxic T-lymphocyte activity. | Atezolizumab binds PD-L1 and blocks its interaction with PD-1 and B7.1 (CD80), enabling restoration of antitumor T-cell responses without direct PD-1 engagement on T cells. |
MoA Biomarker | PD-L1 CPS/TPS (tumor-specific), MSI-H/dMMR, TMB-H (≥10 mut/Mb), and tumor-type-specific biomarkers per label. | PD-1 with slow dissociation and preferential binding in TME-mimicking low | HER2 IHC 3+ or ISH amplified (ASCO/CAP guidelines). | Unresectable Stage III NSCLC post-cCRT (PACIFIC); PD-L1 in other tumors. | PD-L1 IC/TC scoring in NSCLC and UC; tumor-type-specific thresholds. |
PK/PD Half-life | 22 h | 25 h | 4 h | ~21 days (10 mg/kg q2w historical; flat mg dosing per current label) | 27 h |
PK/PD Species | Mouse, Radiographic response, ctDNA clearance in some tumors | Mouse, Objective response, duration of response, exploratory ctDNA clearance | Mouse, OS in metastatic BC | Mouse, OS and PFS benefit in PACIFIC, pCR rates in neoadjuvant trials | Mouse, Human |
PK/PD Animal (cat.) | Mouse, In vitro | Mouse | Mouse, In vitro | Mouse, In vitro | Human, Mouse |
PK/PD Experiment | PD | PD | Pharmacokinetic | PD | PD |
Toxicology Species | Cynomolgus monkey, Macaque, Mouse, Rat | Cynomolgus monkey, Macaque, Mouse | Mouse, Rat | Cynomolgus monkey, Macaque, Mouse | Cynomolgus monkey, Mouse, Human |
Toxicology Animal (cat.) | — | NHP | — | — | — |
Toxicology Major finding | Immune-related AEs | Immune-related adverse reactions: pneumonitis, colitis, hepatitis, hypophysitis, thyroid disorders, nephritis, rash. | Cardiotoxicity (LVEF decline, CHF risk especially with anthracyclines); infusion reactions; myelosuppression in combos. | Immune-related AEs consistent with PD-(L)1 class; radiation pneumonitis overlap monitoring in Stage III NSCLC. | Immune-mediated pneumonitis, hepatitis, colitis, endocrinopathies. |
Toxicology CRS | N/A | N/A (checkpoint inhibitor) | N/A | N/A | N/A |
Clinical Safety signal | Immune-related AEs | Immune-related adverse reactions: pneumonitis, colitis, hepatitis, hypophysitis, thyroid disorders, nephritis, rash. | Cardiotoxicity (LVEF decline, CHF risk especially with anthracyclines); infusion reactions; myelosuppression in combos. | Immune-related AEs consistent with PD-(L)1 class; radiation pneumonitis overlap monitoring in Stage III NSCLC. | Immune-mediated pneumonitis, hepatitis, colitis, endocrinopathies. |
Clinical Selected reported efficacy | ORR 38% | ORR 100% | ORR 91.2% | — | — |
Clinical Reported ORR | 38% | 100% | 91.2% | 0% | — |
Clinical Reported PFS | — | — | — | — | 1.7 |
Clinical Reported OS | — | — | — | — | 7.6 |
Clinical Result source | ClinicalTrials.gov NCT02444741 | ClinicalTrials.gov NCT03267498 | ClinicalTrials.gov NCT02149524 | ClinicalTrials.gov NCT04372927 | ClinicalTrials.gov NCT04457778 |
Clinical Program phase | APPROVED | APPROVED | APPROVED | APPROVED | APPROVED |
Clinical Trial activity | No active/completed counts | No active/completed counts | No active/completed counts | No active/completed counts | No active/completed counts |
Clinical Trial ref | NCT02444741 | NCT03267498 | NCT02149524 | NCT04372927 | NCT04457778 |
Preclinical Animal (cat.) | — | — | — | — | Mouse |
타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-6 · 마지막 9월 2일
현재 선택: 5개 · Data Tier에서 열림
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | durvalumab (Imfinzi, MEDI4736) AstraZeneca·PD-L1 750 trials·t½ ~21 days (10 mg/kg q2w historical; flat mg dosing per current label) | ||||
|---|---|---|---|---|---|
Overview Program | Keytruda (pembrolizumab) | Opdivo (nivolumab) | Herceptin (trastuzumab) | Imfinzi (durvalumab) | Tecentriq (atezolizumab) |
Overview Company | Merck | Bristol Myers Squibb | Roche / Genentech | AstraZeneca | Roche / Genentech |
Overview Modality | ANTIBODY | ANTIBODY | ANTIBODY | ANTIBODY | ANTIBODY |
Overview Target | PD-1 | PD-1 | HER2 | PD-L1 | PD-L1 |
Overview Indication | Multiple solid tumors | Melanoma, NSCLC, RCC, HCC, MSI-H tumors, and others | HER2+ breast cancer, HER2+ gastric/GEJ adenocarcinoma | NSCLC (Stage III consolidation), SCLC, biliary tract, HCC | NSCLC, SCLC, HCC, TNBC, urothelial carcinoma, and others |
Overview Phase | APPROVED | APPROVED | APPROVED | APPROVED | APPROVED |
Overview Status | APPROVED | APPROVED | APPROVED | APPROVED | APPROVED |
Overview Content status | Curated Core | Curated Core | Curated Core | Curated Core | Curated Core |
Overview Data Confidence | Data Confidence · High | Data Confidence · High | Data Confidence · High | Data Confidence · High | Data Confidence · High |
Overview Development Signal | Development Signal · Established | Development Signal · Established | Development Signal · Established | Development Signal · Established | Development Signal · Established |
Overview Approval status | FDA approved | FDA approved | FDA approved | FDA approved | FDA approved |
Positioning Key differentiator | Broad tumor-agnostic biomarker strategies (MSI-H, TMB) | novel approach to enhance antitumor therapy using aPD1 and aCTLA-4 | novel bifunctional chelator (2E-C-NETA) for applications in 177 Lu-based TRT | novel small molecule A 2A R antagonist which inhibits downstream signaling and increases T cell function as well as a novel m | novel agents have been approved in recent years (including systemic pembrolizumab, nogapendekin alfa inbakicept-pmln, N-803), |
Positioning Known limitation | Loss of antigen presentation (β2M, JAK1/2), alternate checkpoints (TIM-3, LAG-3), and immunosuppressive TME. | Loss of MHC-I/antigen presentation, β2M/JAK mutations, TIM-3/LAG-3 upregulation. | resistance to trastuzumab-based targeted therapy and limited intratumoral antibody penetration continue to restrict clinical outcomes | escape detection by the immune system | resistance to existing therapies |
Positioning Development positioning | Global IO standard | — | — | — | — |
MoA Mechanism | Pembrolizumab is an IgG4 humanized monoclonal antibody that binds PD-1 on T cells and blocks interaction with PD-L1 and PD-L2, releasing PD-1 pathway-mediated inhibition of the immune response, including antitumor response. | Nivolumab is a human IgG4 monoclonal antibody that binds the PD-1 receptor on T cells, blocking interaction with PD-L1 and PD-L2 and releasing PD-1 pathway-mediated inhibition of antitumor immune responses. | Trastuzumab binds domain IV of HER2, inhibiting ligand-independent HER2 signaling, mediating ADCC via Fcγ receptors, and inducing internalization/degradation of HER2. | Durvalumab inhibits PD-L1 binding to PD-1 and CD80 (B7.1), counteracting tumor immune evasion and enhancing cytotoxic T-lymphocyte activity. | Atezolizumab binds PD-L1 and blocks its interaction with PD-1 and B7.1 (CD80), enabling restoration of antitumor T-cell responses without direct PD-1 engagement on T cells. |
MoA Biomarker | PD-L1 CPS/TPS (tumor-specific), MSI-H/dMMR, TMB-H (≥10 mut/Mb), and tumor-type-specific biomarkers per label. | PD-1 with slow dissociation and preferential binding in TME-mimicking low | HER2 IHC 3+ or ISH amplified (ASCO/CAP guidelines). | Unresectable Stage III NSCLC post-cCRT (PACIFIC); PD-L1 in other tumors. | PD-L1 IC/TC scoring in NSCLC and UC; tumor-type-specific thresholds. |
PK/PD Half-life | 22 h | 25 h | 4 h | ~21 days (10 mg/kg q2w historical; flat mg dosing per current label) | 27 h |
PK/PD Species | Mouse, Radiographic response, ctDNA clearance in some tumors | Mouse, Objective response, duration of response, exploratory ctDNA clearance | Mouse, OS in metastatic BC | Mouse, OS and PFS benefit in PACIFIC, pCR rates in neoadjuvant trials | Mouse, Human |
PK/PD Animal (cat.) | Mouse, In vitro | Mouse | Mouse, In vitro | Mouse, In vitro | Human, Mouse |
PK/PD Experiment | PD | PD | Pharmacokinetic | PD | PD |
Toxicology Species | Cynomolgus monkey, Macaque, Mouse, Rat | Cynomolgus monkey, Macaque, Mouse | Mouse, Rat | Cynomolgus monkey, Macaque, Mouse | Cynomolgus monkey, Mouse, Human |
Toxicology Animal (cat.) | — | NHP | — | — | — |
Toxicology Major finding | Immune-related AEs | Immune-related adverse reactions: pneumonitis, colitis, hepatitis, hypophysitis, thyroid disorders, nephritis, rash. | Cardiotoxicity (LVEF decline, CHF risk especially with anthracyclines); infusion reactions; myelosuppression in combos. | Immune-related AEs consistent with PD-(L)1 class; radiation pneumonitis overlap monitoring in Stage III NSCLC. | Immune-mediated pneumonitis, hepatitis, colitis, endocrinopathies. |
Toxicology CRS | N/A | N/A (checkpoint inhibitor) | N/A | N/A | N/A |
Clinical Safety signal | Immune-related AEs | Immune-related adverse reactions: pneumonitis, colitis, hepatitis, hypophysitis, thyroid disorders, nephritis, rash. | Cardiotoxicity (LVEF decline, CHF risk especially with anthracyclines); infusion reactions; myelosuppression in combos. | Immune-related AEs consistent with PD-(L)1 class; radiation pneumonitis overlap monitoring in Stage III NSCLC. | Immune-mediated pneumonitis, hepatitis, colitis, endocrinopathies. |
Clinical Selected reported efficacy | ORR 38% | ORR 100% | ORR 91.2% | — | — |
Clinical Reported ORR | 38% | 100% | 91.2% | 0% | — |
Clinical Reported PFS | — | — | — | — | 1.7 |
Clinical Reported OS | — | — | — | — | 7.6 |
Clinical Result source | ClinicalTrials.gov NCT02444741 | ClinicalTrials.gov NCT03267498 | ClinicalTrials.gov NCT02149524 | ClinicalTrials.gov NCT04372927 | ClinicalTrials.gov NCT04457778 |
Clinical Program phase | APPROVED | APPROVED | APPROVED | APPROVED | APPROVED |
Clinical Trial activity | No active/completed counts | No active/completed counts | No active/completed counts | No active/completed counts | No active/completed counts |
Clinical Trial ref | NCT02444741 | NCT03267498 | NCT02149524 | NCT04372927 | NCT04457778 |
Preclinical Animal (cat.) | — | — | — | — | Mouse |
추천 비교
추천 비교